Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 4/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30445234 | 0.76 | GRM5 (0.45) | EGLN1GRM5IRAK4PANK3 | |
| SCHEMBL20575343 | 0.76 | GRM5 (0.45) | EGLN1GRM5IRAK4PANK3 | |
| SCHEMBL14688583 | 0.75 | EGLN1 (0.75) | EGLN1ALKBH2GRM5 | |
| SCHEMBL29556787 | 0.75 | EGLN1 (0.75) | EGLN1ALKBH2GRM5 | |
| SCHEMBL24135253 | 0.74 | GRM5 (0.46) | GRM5IRAK4PANK3 | |
| SCHEMBL15779258 | 0.74 | IRAK4 (0.44) | EGLN1GRM5ALKBH1IRAK4 | |
| SCHEMBL19955388 | 0.73 | EGLN1 (0.43) | EGLN1IRAK4SCN9A | |
| SCHEMBL30535093 | 0.72 | DHX9 (0.46) | — | |
| SCHEMBL25433338 | 0.72 | DHX9 (0.46) | — | |
| SCHEMBL7718659 | 0.72 | MYC (0.47) | GRM5MYCEGLN2SCN9AVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339550-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | EGLN1 3938/4885ALKBH2 3631/4885GRM5 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.